Fanatec’s new Bentley GT3 steering wheel is ... as a two time outright PPHC winner and a 12-time class winner. The QR2 Pro Wheel-Side quick release is the same used on other real-world steering ...

Apple’s iPhone Pro models are some of the most popular smartphones available. The classic three-camera array can be spotted everywhere you go, and that’s no surprise as those devices remain ...

(RTTNews) - At the Annual General Meeting, Paul McKenzie, Chief Executive Officer of CSL Ltd. (CSL.AX), reaffirmed the company's financial guidance for fiscal year 2025. The company still expects ...

Smartphones are constantly getting bigger, and the Apple iPhone 16 Pro Max and Google Pixel 9 Pro XL both stretch the boundaries of what’s comfortable to use with one hand. Thankfully ...

The PS5 Pro is a superb console and now the best PlayStation 5 machine available. The advancements are glorious and bring a new level of immersion and beauty to games, while also boosting ...

CSL (AU:CSL) has released an update. CSL Limited is hosting its 2024 Research & Development Investor Briefing, offering investors insights into the company’s latest innovations and strategic ...

Shares of building envelope solutions provider Carlisle Companies (NYSE:CSL) fell 8.4% in the morning session after the company reported disappointing third-quarter earnings results. Its revenue ...

Xiaomi will unveil the 15 and 15 Pro smartphones at an event on October 29, and ahead of that it's started to run a steady teaser campaign, revealing a few details about them along the way.

The iPhone 16 Pro Max is here, leading the way as Apple’s top-tier phone for 2024. That honor doesn’t come cheap, with the Pro Max starting at $1199 and going all the way up to $1599 if you ...

Let the Ultra-fication of the Pros continue - the vivo X200 Pro is getting the superb telephoto camera of the X100 Ultra, an upgrade in battery tech (and capacity), plus the mandatory new chipset.

Carlisle Companies Inc (NYSE:CSL) achieved record third-quarter results in both EBITDA margin and earnings per share, despite challenges in the residential market and weather-related disruptions.

CSL has pulled studies or trials on three therapies and says US regulators have raised manufacturing concerns about a key new treatment in rare late-stage setbacks for the biotechnology giant’s ...